Repligen (NASDAQ:RGEN - Free Report) had its target price lowered by JPMorgan Chase & Co. from $230.00 to $200.00 in a report published on Thursday morning, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company's stock.
A number of other equities analysts have also recently commented on RGEN. KeyCorp raised their target price on Repligen from $210.00 to $220.00 and gave the stock an overweight rating in a report on Thursday, February 15th. Stifel Nicolaus increased their price target on Repligen from $165.00 to $207.00 and gave the stock a buy rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $195.70.
Get Our Latest Report on Repligen
Repligen Stock Performance
Repligen stock traded up $7.95 during trading on Thursday, reaching $166.31. The company had a trading volume of 848,499 shares, compared to its average volume of 542,138. Repligen has a 52 week low of $110.45 and a 52 week high of $211.13. The firm's 50-day simple moving average is $181.94 and its 200 day simple moving average is $173.85. The firm has a market capitalization of $9.29 billion, a price-to-earnings ratio of 230.99, a price-to-earnings-growth ratio of 5.38 and a beta of 1.03. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same period in the prior year, the business posted $0.64 earnings per share. Repligen's revenue for the quarter was down 17.1% compared to the same quarter last year. Sell-side analysts forecast that Repligen will post 1.46 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Ralf Kuriyel sold 3,517 shares of the firm's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,597 shares of company stock worth $5,039,532. Corporate insiders own 1.20% of the company's stock.
Institutional Trading of Repligen
Institutional investors have recently added to or reduced their stakes in the company. YHB Investment Advisors Inc. bought a new stake in shares of Repligen during the first quarter valued at approximately $26,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 146 shares in the last quarter. Signaturefd LLC raised its stake in shares of Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 86 shares in the last quarter. Principal Securities Inc. bought a new position in Repligen in the fourth quarter worth approximately $48,000. Finally, Milestone Investment Advisors LLC bought a new position in Repligen in the third quarter worth approximately $61,000. Institutional investors own 97.64% of the company's stock.
About Repligen
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
